Ally Bridge Group

Founded 2013
Founders Frank Yu

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 50
Average round size
info
The average size of a deal this fund participated in
$83M
Portfolio companies 45
Rounds per year 6.25
Lead investments 9
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.18
Exits 19
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Medical Device
  • Pharmaceutical
Summary

In 2013 was created Ally Bridge Group, which is appeared as VC. The main office of represented VC is situated in the Hong Kong. The company was established in Asia in Hong Kong.

Among the various public portfolio startups of the fund, we may underline TESARO, GRAIL, Innovent Biologics Besides, a startup needs to be aged 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Pharmaceutical. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.

The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 26 percentage points more often commits exit comparing to other companies. Opposing the other organizations, this Ally Bridge Group works on 0 percentage points more the average amount of lead investments. The higher amount of exits for fund were in 2018. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. Deals in the range of 50 - 100 millions dollars are the general things for fund. The average startup value when the investment from Ally Bridge Group is 500 millions - 1 billion dollars.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Ally Bridge Group, startups are often financed by New Enterprise Associates, Kleiner Perkins, F-Prime Capital. The meaningful sponsors for the fund in investment in the same round are Rock Springs Capital, New Enterprise Associates, Hillhouse Capital Group. In the next rounds fund is usually obtained by Venrock, T. Rowe Price, Sofinnova Partners.

This organization was formed by Frank Yu. The overall number of key employees were 3.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Ally Bridge Group:
Typical Co-investors
Ally Bridge Group is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Ally Bridge Group:

Funds with similar focus

Funds from China, Hong Kong Island
Funds with similar focus located in China, Hong Kong Island:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Kogito Ventures Poland, Warsaw
AllBright United Kingdom, London
Kitty Hawk United States, Mountain View
SierraMaya360 United States, Los Angeles
GlobalFoundries United States, Santa Clara
US Ecology United States, Boise
Franciscan Sisters of Mary United States, Bridgeton
ZM Invest Poland, Ropczyce
Startupbootcamp Amsterdam The Netherlands, Amsterdam
Florida Gulfshore Capital United States, Naples
Ecosystem Integrity Fund United States, San Francisco
Sodero Gestion France, Nantes
Presight Capital United States, New City
Oak Hill Advisors United States, New York
Virginia Active Angel Network United States, Charlottesville
Ju Shi Chuang Tou China, Nanjing
KT Squared -
Myventure Partners South Korea, Seoul
Acrodea Japan, Minato
Earl Grey Capital -

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Imperative Care

Health Care
Medical
Medical Device
1
$260M15 Jul 2021 United States, " United States"}

Nautilus Biotechnology

Biotechnology
Life Science
Pharmaceutical
n/a
$200M10 Jun 2021 United States, " United States"}

NiKang Therapeutics

Biotechnology
Health Care
Medical
1
$200M26 May 2021 United States, Wilmington

Vida Health

Health Care
Medical
mHealth
Personal Health
Therapeutics
1
$110M05 May 2021 United States, San Francisco

Ultivue

Biopharma
Biotechnology
Pharmaceutical
1
$50M27 Apr 2021 United States, Cambridge

RefleXion Medical

Health Care
Medical
Medical Device
Therapeutics
1
$40M02 Mar 2021 United States, Hayward

Mainstay Medical

Biotechnology
Emergency Medicine
Health Care
Medical
Medical Device
1
$108M16 Feb 2021 Ireland, Dublin

Cyteir Therapeutics

Biopharma
Biotechnology
Pharmaceutical
1
$80M11 Feb 2021 United States, Cambridge

IsoPlexis

Biotechnology
Health Care
Medical Device
Therapeutics
1
$50M07 Jan 2021 United States, " United States"}
News
Elligo Health Research Inks $135M Series E

– Elligo Health Research, a healthcare-enabling research organization powered by the novel IntElligo technology, announced a $135m Series E financing round.
Morgan Stanley Expansion Capital and Ally Bridge Group participated in the financing round.
– The round was also participated by Norwest Venture Partners and all major existing investors, including Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler Merchant Banking, Shumway Capital, and Syneos Health.
– This financing allows Elligo to invest further in its technology platform and leverage data in new ways to address current challenges in the clinical trial industry.

Imperative Care Raises $260 Million to Advance Innovations that Elevate Stroke Care

– Imperative Care, Inc. announced that it has closed a $260m Series D financing led by D1 Capital Partners.
– New investors HealthCor Investments LLC and Innovatus Capital Partners also joined the round. Existing Imperative Care investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, and Amed Ventures participated in the financing.
– James Rogers from D1 will join Imperative Care’s Board of Directors.
– Proceeds from the financing will be used to support ongoing commercialization and development of a wide range of Imperative Care’s technologies in the broad continuum of stroke care, as well as to create a strategic network of wholly owned development subsidiaries in a number of areas of synergy.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Ally Bridge Group?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: